flutiform 125 mikrog/ dose / 5 mikrog/ dose
2care4 - flutikasonpropionat / formoterolfumaratdihydrat - inhalasjonsaerosol, suspensjon - 125 mikrog/ dose / 5 mikrog/ dose
lidocaine accord 10 mg/ ml
accord healthcare b.v. - lidokainhydroklorid - injeksjonsvæske, oppløsning - 10 mg/ ml
lidocaine accord 20 mg/ ml
accord healthcare b.v. - lidokainhydroklorid - injeksjonsvæske, oppløsning - 20 mg/ ml
technescan pyp 20 mg
curium netherlands b.v. - natriumpyrofosfat - preparasjonssett til radioaktive legemidler - 20 mg
teceos 13 mg
cis bio international - butedronatetetranatrium - preparasjonssett til radioaktive legemidler - 13 mg
dacarbazine lipomed 500 mg
lipomed gmbh - dakarbazin - pulver til infusjonsvæske, oppløsning - 500 mg
dacarbazine lipomed 1000 mg
lipomed gmbh - dakarbazin - pulver til infusjonsvæske, oppløsning - 1000 mg
flutiform k-haler 125 mikrog / 5 mikrog
mundipharma as - flutikasonpropionat / formoterolfumaratdihydrat - inhalasjonsaerosol, suspensjon - 125 mikrog / 5 mikrog
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.